Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3090 | Probiotic Wiki | 0.41 |
| drug2916 | Placebo Wiki | 0.06 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Description: The number of days from the date of receipt of a positive SARS-CoV-2 swab test result to the date of first dose of study drug in asymptomatic subjects who: have SARS-CoV-2 detected on a surveillance nasal or nasopharyngeal swab OR live in the same house or apartment as someone who has laboratory-confirmed symptomatic COVID-19
Measure: To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years Time: Beginning of randomization through Week 2Description: Study drug compliance determined from the number of capsules of study drug taken by the subject based on data reported in an eDiary
Measure: To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population Time: Beginning of randomization through Week 2Description: Study drug compliance determined from the number of capsules of study drug taken by the subject based on data from twice weekly phone calls
Measure: To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population Time: Beginning of randomization through Week 2Description: Study drug compliance determined from the number of capsules of study drug taken by the subject based on a pill count done by phone when subjects complete study drug treatment
Measure: To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population Time: Beginning of randomization through Week 2Description: Incidence and severity of COVID-19 symptoms based on data reported in an eDiary
Measure: To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population Time: From time of first dose through Week 3Description: Incidence and severity of COVID-19 symptoms based on data from twice weekly phone calls
Measure: To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population Time: From time of first dose through Week 3Description: Safety and tolerability will be assessed by report of AE/SAEs from first dose of study drug through Week 3
Measure: To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo Time: From time of first dose through Week 3Description: The percentage of subjects who have SARS-CoV-2 detected on nasal or nasopharyngeal swab and who develop 2 or more concurrent symptoms of COVID-19 from first dose of study drug through Day 14
Measure: To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14 Time: From time of first dose through Week 2Description: The percentage of subjects who die from any cause from first dose of study drug through Day 14 and 21
Measure: To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21 Time: From time of first dose through Week 3Description: The percentage of subjects who develop laboratory-confirmed COVID-19 from first dose of study drug through Day 14 and are subsequently hospitalized for any reason through Day 21
Measure: To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21 Time: From time of first dose through Week 3Description: The percentage of subjects who have SARS-CoV-2 detected on nasal or nasopharyngeal swab regardless of symptoms from first dose of study drug through Day 7, 14, and 21 among subjects who are not SARS-CoV-2 positive at screening or baseline
Measure: To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21. Time: From time of first dose through Week 3Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports